Continuing decline in hormone therapy use: population trends over 17 years

References

• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• The Board of the International Menopause Society. IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 181–194
   PubMed Web of Science ®Google Scholar
• MacLennan A H, Myers S P, Taylor A W. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 2006; 84: 27–31
   Google Scholar
• MacLennan A H, Broadbent J L, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No CD002978. DOI: 10.1002/14651858.CD002978.pub2
   PubMedGoogle Scholar
• Nedrow A, Miller J, Walker M, Nygren P, Huffman L H, Nelson H D. Complementary and alternative therapies for the management of menopause-related symptoms. A systematic evidence review. Arch Intern Med 2006; 166: 1453–1465
   PubMed Web of Science ®Google Scholar
• ACOG Committee Opinion. Compounded bioidentical hormones. Obstet Gynecol 2005; 106: 1139–1140
   PubMedGoogle Scholar
• MacLennan A H, Sturdee D W. The ‘bioidentical/bioequivalent’ hormone scam. Climacteric 2006; 9: 1–3
   PubMed Web of Science ®Google Scholar
• MacLennan A H, MacLennan A, Wilson D. The prevalence of oestrogen replacement therapy in South Australia. Maturitas 1993; 16: 175–183
   PubMed Web of Science ®Google Scholar
• MacLennan A H, Taylor A W, Wilson D H. Changes in the use of hormone replacement therapy in South Australia. Med J Aust 1995; 162: 420–422
   PubMed Web of Science ®Google Scholar
• MacLennan A H, Wilson D H, Taylor A W. Hormone replacement therapy – prevalence, compliance and the ‘healthy woman’ notion. Climacteric 1998; 1: 42–49
   PubMedGoogle Scholar
• MacLennan A H, Wilson D, Taylor A W. Hormone replacement therapy use over a decade in an Australian population. Climacteric 2002; 5: 351–356
   PubMed Web of Science ®Google Scholar
• MacLennan A H, Taylor A W, Wilson D H. Hormone therapy use after the Women's Health Initiative. Climacteric 2004; 7: 138–142
   PubMed Web of Science ®Google Scholar
• MacLennan A H, Taylor A W, Wilson D H. The escalating cost and prevalence of alternative medicine. Prev Med 2002; 35: 166–173
   PubMed Web of Science ®Google Scholar
• MacLennan A H, Taylor A W, Wilson D H, Wilson D. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. Br J Obstet Gynaecol 2000; 107: 1460–1470
   Google Scholar
• Wilson D, Taylor A, Roberts L. Can we target smoking groups more effectively? A study of male and female heavy smokers. Prev Med 1995; 24: 363–368
   PubMed Web of Science ®Google Scholar
• Wilson D, Wakefield M A, Taylor A. The South Australian Health Omnibus Survey. Health Promotion J Aust 1992; 2: 47–49
   Google Scholar
• Ware J E, Kosinski M, Dewey J. How to Score Version 2 of the SF-36 Health Survey. Quality Metric Incorporated, Lincoln, RI 2000
   Google Scholar
• Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Area's (SEIFA). Technical Paper. Australia 2001. Catalogue number. 2039.0.55. 001. Australian Bureau of Statistics, Canberra 2004
   Google Scholar
• Rousseau J E, Prentice R L, Manson J E, et al. Postnatal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–1477
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee D W, MacLennan A H, Schneider H PG, Burger H, Fenton A. The heart of the WHI study: time for hormone therapy policies to be revised. Climacteric 2007; 10: 267–269
   PubMed Web of Science ®Google Scholar
• Kim N, Gross C, Curtis J, et al. The impact of clinical trials on the use of hormone replacement therapy. a population-based study. J Gen Intern Med 2005; 20: 1026–1031
   PubMed Web of Science ®Google Scholar
• Anderson G L, Chlebowski R T, Rossouw J E, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial plus progestin. Maturitas 2006; 55: 103–105
   PubMed Web of Science ®Google Scholar
• Sturdee D, MacLennan A H. Should epidemiology, the media and quangos determine clinical practice. Climacteric 2004; 7: 1–2
   PubMed Web of Science ®Google Scholar
• Nedrow A, Miller J, Walker M, Nygren P, Huffman L H, Nelson H D. Complementary and alternative therapies for the management of menopause-related symptoms. a systematic evidence review. Arch Intern Med 2006; 166: 1453–1465
   PubMed Web of Science ®Google Scholar
• Reed S D, Newton K M, LaCroix A Z, Grothaus L C, Grieco V S, Ehrlich K. Vaginal, endometrial,and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) study. Menopause 2008; 15: 51–58
   PubMed Web of Science ®Google Scholar
• Adverse Drug Reactions Advisory Committee. Black cohosh and liver toxicity – an update. Aust Adverse Drug Reactions Bull 2007; 26: 11
   Google Scholar
• Boothby L A, Doering P L, Kipersztok S. Bioidentical hormone therapy: a review. Menopause 2004; 11: 356–367
   PubMed Web of Science ®Google Scholar
• Rosenthal M S. The Wiley Protocol: an analysis of ethical issues. Menopause 2008; 15: 1014–1022
   PubMed Web of Science ®Google Scholar